ASHLEY I BUSH, M.D.
Psychiatric in Somerville, MA

6638711, Oct 28, 2003

Apr 28, 2000

09/560883

Ashley I. Bush - Somerville MA
Xudong Huang - Andover MA
Craig S. Atwood - Brecksville OH
Rudolph E. Tanzi - Hull MA

The General Hospital Corporation - Boston MA

C12Q 100

435 4, 436 80, 436 84, 436127, 530350

The invention relates to methods for identifying candidate pharmacological agents to be used in the treatment and/or prevention of Alzheimers disease and/or related pathological conditions.

8318171, Nov 27, 2012

May 14, 2009

12/466094

Ashley Bush - Somerville MA, US
Robert Cherny - Brighton East, AU

Prana Biotechnology Limited - Victoria
The General Hospital Corporation - Boston MA

A61K 39/395

4241721

This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

2005014, Jun 30, 2005

Feb 23, 2005

11/064539

David Darby - West Melbourne, AU
Ashley Bush - Somerville MA, US
Paul Maruff - Ivanhoe, AU
Alex Collie - Kensington, AU

CogState, Ltd - Carlton

A61B005/00

600300000

A system and method of diagnosing the onset and monitoring the progression of cognitive impairment may incorporate administering one or more psychological tests and instructing a subject regarding rules for responding to the one or more tests without providing cultural cues such as may be introduced in language-based instruction techniques. Proper test responses may be simulated during an instruction phase preceding the testing phase. An apparatus, system, and method of testing cognitive function may be implemented in a computerized system.

7107092, Sep 12, 2006

Aug 21, 2001

09/935126

Lee E. Goldstein - Marblehead MA, US
Ashley Ian Bush - Somerville MA, US

The General Hospital Corporation - Boston MA
The Brigham and Women's Hospital, Inc. - Boston MA

A61B 6/00

600476, 316318, 316319, 316407, 800 8, 800 9, 800 12, 351214, 424 91, 424 96, 4241851, 435 4, 435 6, 435 74, 356300

A method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.

5972634, Oct 26, 1999

Aug 4, 1997

8/817423

Rudolph E. Tanzi - Canton MA
Ashley I. Bush - Somerville MA
Robert D. Moir - Boston MA

The General Hospital Corporation - Boston MA

G01N 3353

435 794

The disclosed invention relates to assays for detecting and quantifying A. beta. peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A. beta. peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A. beta. peptides from biological fluids are taught.

7045531, May 16, 2006

Mar 11, 1998

09/380704

Ashley I. Bush - Somerville MA, US
Xudong Huang - Cambridge MA, US
Craig S. Atwood - Cleveland OH, US
Rudolph E. Tanzi - Hull MA, US

The General Hospital Corporation - Boston MA

A61K 31/47, A61K 31/53, A61K 31/40, A61K 31/105

514311, 514244, 514420, 514707

The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, Aβ-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.

7618634, Nov 17, 2009

Jun 28, 2001

10/312437

Ashley Bush - Somerville MA, US
Robert Cherny - Brighton East, AU
Rudolph Emile Tanzi - Hull MA, US

Prana Biotechnology Limited - South Melbourne, Victoria
The General Hospital Corporation - Boston MA

A61K 39/00, A61K 38/00, A61K 38/04

4241851, 530300, 530328

This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

6323218, Nov 27, 2001

Mar 11, 1998

9/038154

Ashley I. Bush - Somerville MA
Xudong Huang - Cambridge MA
Craig S. Atwood - Somerville MA
Rudolph E. Tanzi - Canton MA

The General Hospital Corporation - Boston MA

A61K 3147, A61K 3153, A61K 3140, A61K 31105

514311

The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions and compositions for treatment of conditions caused by amyloidosis, A. beta. -mediated formation of ROS, or both, such as Alzheimer's disease.

6890727, May 10, 2005

Oct 25, 1999

09/425956

Rudolph E. Tanzi - Canton MA, US
Ashley I. Bush - Somerville MA, US
Robert D. Moir - Boston MA, US

The General Hospital Corporation - Boston MA

G01N033/53

435 794, 435 79, 435 792, 435 795, 435 71, 435975, 436525, 436 164, 436172, 5303891

The disclosed invention relates to assays for detecting and quantifying Aβ peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of Aβ peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of Aβ peptides from biological fluids are taught.

7653428, Jan 26, 2010

Aug 28, 2006

11/511916

Lee E. Goldstein - Marblehead MA, US
Ashley Ian Bush - Somerville MA, US

The Brigham and Women's Hospital, Inc. - Boston MA

A61B 6/00

600476, 600316, 600318, 600319, 600407, 600477, 424 91, 424 96, 4241851, 351214, 435 4, 435 6, 435 74, 356300

The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.